ArticleFrontiers in pharmacology2026
The effect of scheduled metamizole on opioid consumption after cardiac surgery.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study evaluates the impact of implementing a standardized scheduled metamizole dosing protocol within a multimodal analgesia approach after cardiac surgery. The results showed that scheduled metamizole administration was associated with lower opioid consumption, while maintaining adequate pain control and safety. Pain scores measured by the Numeric Rating Scale improved from 1.12 pre-protocol to 0.89 post-protocol (p < 0.0001). Mean opioid consumption decreased from 119.51 mg morphine equivalents to 95.91 mg (p < 0.0001). No cases of clinically relevant agranulocytosis or persistent neutropenia were observed. Renal function, assessed by changes in serum creatinine, showed no significant differences between groups, suggesting renal safety. Despite improved analgesia and reduced opioid use, hospital length of stay increased slightly, potentially due to confounding factors. Our findings support scheduled metamizole as a safe and effective opioid-sparing agent in postoperative cardiac surgery pain management. Further prospective randomized trials are warranted to confirm these results and establish optimal protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.